cardiac stem cells therapy / Brigham and Womens Hospital - LARVOL DELTA

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - P2; N=20; Recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Trial primary completion date: Oct 2015 ➔ Apr 2016

Trial primary completion date • Biosimilar

A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer (clinicaltrials.gov) - P4; N=49; Active, not recruiting; Sponsor: Hoffmann-La Roche; Completed ➔ Active, not recruiting; Trial primary completion date: Jan 2015 ➔ Nov 2015

Enrollment closed • Trial primary completion date • Biosimilar • Breast Cancer • Oncology • Triple Negative Breast Cancer

Clinical trial to determinate viral load in seminal fluid in HIV-positive patients without previous treatment Ensayo clinico para medir la carga viral en el semen de pacientes VIH que no han recibido tratamiento antirretroviral previamente (clinicaltrialsregister.eu) - P2; N=36; Ongoing; Sponsor: Fundación pública andaluza para la gestión de la investigación en salud de Sevilla (FISEVI)

New P2 trial • Biosimilar • Immunology • Inflammation

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study) (clinicaltrials.gov) - P3; N=1200; Active, not recruiting; Sponsor: Receptos, Inc.; Trial primary completion date: Nov 2017 ->Apr 2017

Trial primary completion date • Biosimilar • Multiple Myeloma • Multiple Sclerosis

The birth of new cardiac cells (Harvard health publications) - Recent research has shown that there are new cells that develop in the heart, but how these cardiac cells are born & how frequently they are generated remains unclear; In new research from Brigham & Women's Hospital, researchers use a novel method to identify these new heart cells & describe their origins.

Clinical • Heart Failure

Mammalian heart renewal by pre-existing cardiomyocytes (Nature) - Study found that cell cycle activity during normal ageing & after injury led to polyploidy & multinucleation, but also to new diploid, mononucleate cardiomyocytes; Data reveal pre-existing cardiomyocytes as the dominant source of cardiomyocyte replacement in normal mammalian myocardial homeostasis as well as after myocardial injury.

Clinical • Heart Failure

Motor Cortex Stimulation for Parkinson's Disease (clinicaltrials.gov) - P=N/A; N=13; Completed; Sponsor: Catholic University, Italy; Recruiting ➔ Completed; N=20 ➔ 13; Trial primary completion date: Jun 2010 ➔ Jun 2013

Enrollment change • Trial completion • Trial primary completion date • Biosimilar • Parkinson's Disease

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis (clinicaltrials.gov) - P4; N=0; Withdrawn; Sponsor: Astellas Pharma Inc; N=350 ➔ 0

Enrollment change • Biosimilar

Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE (clinicaltrials.gov) - P=N/A; N=1000; Recruiting; Sponsor: Medical University of Vienna; Trial primary completion date: Dec 2013 ->Dec 2015

Trial primary completion date • Biosimilar • Heart Failure • Reperfusion Injury

asn01-Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01) (clinicaltrials.gov) - P3; N=80; Completed; Sponsor: Kyberg Vital GmbH; Recruiting ➔ Completed; N=60 ➔ 80

Enrollment change • Trial completion • Biosimilar

Harvest, Isolation and Culture of Cardiac Stem Cells From Endomyocardial Biopsies (clinicaltrials.gov) - P=N/A; N=0; Withdrawn; Sponsor: University of Louisville; N=30 ➔ 0; Enrolling by invitation ➔ Withdrawn

Enrollment change • Trial withdrawal • Biosimilar • Cardiovascular • Heart Failure

Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure. (clinicaltrials.gov) - P3; N=240; Active, not recruiting; Sponsor: Celyad (formerly named Cardio3 BioSciences); Recruiting -> Active, not recruiting

Enrollment closed • Biosimilar • Heart Failure • Multiple Myeloma • Reperfusion Injury

Safety Study of Rituximab (Rituxan®) in Chronic Urticaria (clinicaltrials.gov) - P1/2; N=15; Terminated; Sponsor: Johns Hopkins University; Suspended ➔ Terminated; Trial primary completion date: Dec 2008 ➔ May 2007

Trial primary completion date • Trial termination • Biosimilar • Immunology • Inflammation

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC (clinicaltrials.gov) - P4; N=100; Completed; Sponsor: Kyoto University; Active, not recruiting ➔ Completed; Trial primary completion date: Sep 2012 ➔ Mar 2012

Trial completion • Trial primary completion date • Biosimilar • Hepatitis C Virus • Hepatocellular Cancer • Immunology • Inflammation • Oncology

Cardiac stem cells in patients with ischemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial (AHA 2012) - Abstract not available

P1 data • Heart Failure

Effect of cardiac stem cells in patients with ischemic cardiomyopathy: Interim results of the SCIPIO trial up to 2 years after therapy (AHA 2012) - Abstract not available

P1 data • Heart Failure

The ALCADIA (Autologous human cardiac-derived stem cell to treat ischemic cardiomyopathy) trial (AHA 2012) - Abstract not available

P1 data • Heart Failure